US Stock MarketDetailed Quotes

RLMD Relmada Therapeutics

Watchlist
  • 2.500
  • -0.070-2.72%
Close Aug 16 16:00 ET
  • 2.500
  • 0.0000.00%
Post 20:02 ET
75.44MMarket Cap-871P/E (TTM)

Relmada Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Relmada Therapeutics Q2 2024 Earnings Date

Currency：USDAug 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.83
-0.59
+0.24
Beat Est.
+1.49%
+29.76%
+28.69%
Analyst Rating
Buy

Aug 9, 2024

Relmada Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2020/Q3-- / 0.000--
--2020/Q2-- / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--
Mar 19, 20242023/Q40.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2020/Q3-- / 0.000--
--2020/Q2-- / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--
Mar 19, 20242023/Q40.000 / 0.000--

Unlock Free Earnings Estimates

Relmada Therapeutics Earnings Reports

  • Relmada Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 7 16:10 ET

  • Relmada Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 8 16:13 ET

  • Relmada Therapeutics | 10-K: FY2023 Annual Report

    Mar 19 16:11 ET

  • Relmada Therapeutics | 10-Q: Q3 2023 Earnings Report

    Nov 8, 2023 16:05 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 9, 2024

    Buy

    • Buy

      66.67%

    • Hold

      0.00%

    • Sell

      33.33%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg